CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.58
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$270.25

22 Jan
2025

-3.170

OPEN

$273.38

-1.16%

HIGH

$273.87

854,599

LOW

$270.25

TARGET
$333.792 23.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 1030.5 xxx
DPS (cps) 461.3 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 26.2 xxx
Dividend Yield 1.7% xxx
Div Pay Ratio(%) 44.8% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.60%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.56

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx834.7
DPS All xxxxxxxxxxxxxxx397.4
Sales/Revenue xxxxxxxxxxxxxxx22,417.6 M
Book Value Per Share xxxxxxxxxxxxxxx5,379.9
Net Operating Cash Flow xxxxxxxxxxxxxxx4,218.0 M
Net Profit Margin xxxxxxxxxxxxxxx17.99 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx16.22 %
Return on Invested Capital xxxxxxxxxxxxxxx9.68 %
Return on Assets xxxxxxxxxxxxxxx7.24 %
Return on Equity xxxxxxxxxxxxxxx16.22 %
Return on Total Capital xxxxxxxxxxxxxxx12.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,103.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1,413 M
Long Term Debt xxxxxxxxxxxxxxx16,829 M
Total Debt xxxxxxxxxxxxxxx18,242 M
Goodwill - Gross xxxxxxxxxxxxxxx12,097 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,481 M
Price To Book Value xxxxxxxxxxxxxxx5.49

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1,919.8 M
Capex % of Sales xxxxxxxxxxxxxxx8.56 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,505 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5,263 M
Research & Development xxxxxxxxxxxxxxx2,182 M
Investments - Total xxxxxxxxxxxxxxx244 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

03/12/2024

1

Outperform

$334.00

23.59%

Macquarie's new gross margin assumptions for CSL Behring imply a return to pre-covid levels of around 57% by FY28 compared to FY27 previously.

This change is a result of the analyst adopting a more conservative stance on the ramp-up of Rika platform yield benefits.

Macquarie suggests current share price levels are an attractive entry point for investors.

Outperform rating and the broker's target for CSL rises to $334 from $330.

FORECAST
Macquarie forecasts a full year FY25 dividend of 473.44 cents and EPS of 1039.73 cents.
Macquarie forecasts a full year FY26 dividend of 572.38 cents and EPS of 1234.59 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

1

xx-xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

30/10/2024

2

Overweight

$329.62

21.97%

Jarden observes moderate delays and FDA uncertainties in the R&D pipeline for CSL, with mixed outcomes across projects.

Prominent developments are the Horizon 2 project, expected to drive substantial Ig yield improvements but facing regulatory clarifications, and GARADACIMAB, which awaits FDA re-approval after procedural delays.

The broker notes the pipeline also shows new product directions like nebulised IgG and self-amplifying mRNA vaccines.

No changes to Overweight rating and $329.62 target price. Jarden  points to CSL’s ongoing Vifor integration and sector competition as ongoing risks.

FORECAST
Jarden forecasts a full year FY25 dividend of 456.69 cents and EPS of 925.56 cents.
Jarden forecasts a full year FY26 dividend of 462.48 cents and EPS of 1150.86 cents.

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

CSL STOCK CHART

FNArena News on CSL

1
Rudi’s View: Feb Season’s Best Buys & Key Picks

Jan 23 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Jan 20, 2025

Jan 20 2025 - Daily Market Reports
3
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View
4
Rudi’s View: All-Weather Portfolio In 2024

Jan 15 2025 - Rudi's View
5
Ask FNArena: What To Buy (Pre & Post Correction)

Dec 24 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps